ICU Medical Inc（ICUI）の財務ICUIICU Medical Inc

ICU Medical, Inc. (ICUI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Infusion Consumables, accounting for 52.4% of total sales, equivalent to $289.28M. Other significant revenue streams include Consumables and Infusion Systems. Understanding this composition is critical for investors evaluating how ICUI navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, ICU Medical, Inc. maintains a gross margin of 42.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.95%, while the net margin is 3.46%. These profitability ratios, combined with a Return on Equity (ROE) of 1.41%, provide a clear picture of how effectively ICUI converts its operational activities into shareholder value.

In the context of the broader market, ICUI competes directly with industry leaders such as PLSE and LIVN. With a market capitalization of $3.82B, it holds a significant position in the sector. When comparing efficiency, ICUI's gross margin of 42.61% stands against PLSE's 37.10% and LIVN's 68.09%. Such benchmarking helps identify whether ICU Medical, Inc. is trading at a premium or discount relative to its financial performance.

ICU Medical has shown significant improvement in its financials, with a gross margin of 42.61% in Q2 2026, up from 37.91% in Q2 2025. The company also reported a net income of $19.1 million in Q2 2026, a positive turnaround from previous quarters.